CT-CSPC@EC2606B(20050.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
CT-CSPC@EC2606B
20050.HK
News
View More

Top 5 HK Stock Gainers/Losers (>100B) (2.3)

MINIMAX-WP(00100) rose 10.98%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 252.1%. KNOWLEDGE ATLAS(02513) rose 8.28%, with a trading turnover 616.0 Million HKD, and a year-to-date rose 109.3%. HTSC(06886) fell 8.24%, with a trading turnover 1.6 Billion HKD, and a year-to-date fell 10%. KUAISHOU-W(01024) fell 4.61%, with a trading turnover 5.1 Billion HKD, and a year-to-date rose 14.9%.

Top Gainers & Losers·
HK
00100
+10.98%
HK
02513
+8.28%
HK
01093
+8.09%
Top Gainers & Losers·
HK
00100
+10.98%
HK
02513
+8.28%
HK
01093
+8.09%

Huatai Securities Reaffirms Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)

Huatai Securities has reaffirmed a Buy rating on CSPC Pharmaceutical Group (CHJTF), setting a price target of HK$19.25, while the stock closed at HK$9.15. The analyst consensus is a Moderate Buy with an average price target of HK$11.56, indicating a 26.33% upside. Additionally, CMB International Securities also maintains a Buy rating with a price target of HK$13.93.

Tip Ranks·
SH
513120
+2.04%
HK
01093
+8.09%
Tip Ranks·
SH
513120
+2.04%
HK
01093
+8.09%

The Hang Seng Index rose 54 points in the half-day session, tech stocks collectively plummeted, aerospace stocks surged, and Tencent dragged down 62 points | Hong Kong stock market midday

The Hang Seng Index opened 220 points higher this morning, but the gains narrowed later, with a minimum drop of 344 points. It ultimately closed at 26,830 points, up 54 points or 0.2%. The Tech Index reported 5,453 points at noon, down 72 points or 1.32%. CSPC PHARMA was approved to conduct clinical trials, with its stock price rising 4.15%. Internet stocks such as Kuaishou, Baidu, and Tencent fell by 4.35%, 3.54%, and 3.09% respectively. Commercial aerospace stocks rose collectively, with JunDa rising by as much as 12.95%. The three major U.S. stock indices rebounded, easing panic sentiment

Stheadline·
HK
00HSI
+0.22%
HK
00700
-2.92%
HK
07500
-0.48%
Stheadline·
HK
00HSI
+0.22%
HK
00700
-2.92%
HK
07500
-0.48%

CITIC International raised the target price of CSPC PHARMA to 13.93 yuan, expecting BD transactions to support profits and dividends

CMB International has raised the target price of CSPC PHARMA to RMB 13.93, maintaining a "Buy" rating. The report indicates that CSPC has signed a strategic cooperation agreement with AstraZeneca, expected to receive a USD 1.2 billion upfront payment and up to USD 17.3 billion in potential milestone payments. The company has signed 6 business expansion agreements, with sales slightly recovering in the third quarter of last year, and core revenue growing 4.2% quarter-on-quarter. BD transactions will continue to drive profit growth and support dividends

AASTOCKS·
HK
01093
+8.09%
AASTOCKS·
HK
01093
+8.09%

CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug

CSPC Pharmaceutical Group has received drug registration approval in mainland China for its fast-acting intravenous antihypertensive drug, Clevidipine Injectable Emulsion. This drug is designed for patients whose hypertension is not effectively managed with oral therapy, offering rapid blood pressure control without the need for dose adjustments. The approval enhances CSPC's cardiovascular product pipeline and addresses the demand for acute-care hypertension treatments in Chinese hospitals. Analysts rate the stock as a Buy with a price target of HK$10.50.

Tip Ranks·
SZ
300765
+3.59%
HK
01093
+8.09%
SH
562050
+1.13%
Tip Ranks·
SZ
300765
+3.59%
HK
01093
+8.09%
SH
562050
+1.13%
Posts
View More
© 2026 Longbridge｜Disclaimer